Represented appellee Watson Pharmaceuticals, Inc. in successful defense of district court’s order dismissing Bayer’s claims of patent infringement. The Federal Circuit agreed with Watson that for a generic drug maker to infringe a method-of-use patent, the proposed label must indicate that the drug is approved (i.e., safe and effective) for the claimed method. Bayer Schering Pharma AG v. Lupin, Ltd., et al., 2012 U.S. App. LEXIS 7570, Fed. Cir. Appeal No. 2011-1143 (April 16, 2012).

Experience Center

Match our Experience to Your Needs

Experience Highlights

Antitrust and business tort litigation for a large maker of electronic test, measurement and monitoring equipment
Successfully represented a large maker of electronic test, measurement and monitoring equipment in an antitrust and business tort action in the more
Patent prosecution and counseling for U.K. Ministry of Defence (MOD)
Represent the U.K. Ministry of Defence (MOD), which is responsible for the military and homeland security functions of the United Kingdom, and have more
Centennial Healthcare going-private transaction
Represented the Special Committee of the Board of Centennial Healthcare, an operator of more than 100 nursing home facilities, in its consideration more
Federal Clean Water Act litigation for Krispy Kreme Doughnut Corporation
Served as lead counsel for Krispy Kreme Doughnut Corporation in a case that arose from allegations by Fairfax County, Virginia that waste water more